PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 96 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $60 | -25.9% | 5,825 | +2.8% | 0.00% | – |
Q2 2023 | $81 | -22.1% | 5,666 | -61.2% | 0.00% | – |
Q1 2023 | $104 | -36.6% | 14,603 | 0.0% | 0.00% | – |
Q4 2022 | $164 | -99.9% | 14,603 | -0.6% | 0.00% | – |
Q3 2022 | $163,000 | +32.5% | 14,686 | +1.0% | 0.00% | – |
Q2 2022 | $123,000 | -37.9% | 14,536 | -0.2% | 0.00% | – |
Q1 2022 | $198,000 | -31.0% | 14,569 | 0.0% | 0.00% | – |
Q4 2021 | $287,000 | -38.8% | 14,569 | -0.3% | 0.00% | – |
Q3 2021 | $469,000 | -20.8% | 14,617 | -16.5% | 0.00% | -100.0% |
Q2 2021 | $592,000 | +62.6% | 17,495 | +80.4% | 0.00% | – |
Q1 2021 | $364,000 | +13.0% | 9,700 | 0.0% | 0.00% | – |
Q4 2020 | $322,000 | -9.6% | 9,700 | 0.0% | 0.00% | – |
Q3 2020 | $356,000 | +11.6% | 9,700 | 0.0% | 0.00% | – |
Q2 2020 | $319,000 | +27.6% | 9,700 | 0.0% | 0.00% | – |
Q1 2020 | $250,000 | -17.2% | 9,700 | 0.0% | 0.00% | – |
Q4 2019 | $302,000 | – | 9,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 5,827,415 | $187,060,000 | 14.97% |
Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $66,378,000 | 14.44% |
Abingworth LLP | 1,203,135 | $38,512,000 | 8.74% |
Penn Mutual Asset Management, LLC | 86,940 | $2,791,000 | 4.41% |
GREAT POINT PARTNERS LLC | 220,863 | $7,090,000 | 1.65% |
RA Capital Management | 3,115,008 | $99,992,000 | 1.39% |
StepStone Group LP | 422,085 | $13,549,000 | 0.88% |
Summit Rock Advisors, LP | 34,100 | $1,094,000 | 0.65% |
Rhenman & Partners Asset Management AB | 186,210 | $5,977,000 | 0.42% |
Eventide Asset Management | 600,000 | $19,260,000 | 0.25% |